James Amatruda, MD, PhD

Professor of Pediatrics

Image of James Amatruda, MD, PhD
Is this your profile? Click to edit

Overview

James F. Amatruda, MD, PhD is Chief of the Division of Hematology-Oncology and Director of the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles; and Professor of Pediatrics and Medicine at the Keck School of Medicine of the University of Southern California. He received his Bachelor’s degree in Biochemical Sciences from Harvard University and his MD,PhD from Washington University School of Medicine. He did internship and residency training in Internal Medicine at the Brigham and Women’s Hospital in Boston, MA, followed by fellowship training in Medical Oncology at Dana-Farber/Partners Cancer Care in Boston, MA. He was a Postdoctoral Fellow in the laboratory of Dr. Leonard Zon at Boston Children’s Hospital, Harvard Medical School. From 2005-2019, Dr. Amatruda was on the faculty of UT Southwestern Medical Center in Dallas, TX.

Dr. Amatruda is a physician-scientist with a primary research and clinical focus on solid tumors of childhood including sarcomas, germ cell tumors and Wilms tumor. His lab has developed zebrafish models of genetic subtypes of pediatric solid tumors to better define their biology and to use that knowledge to identify and validate novel approaches for improved therapies. He has had long-standing leadership positions in the Children’s Oncology Group; serving as Chair for the Germ Cell Tumor Biology Committee and the Rare Tumors Biology Committee. He also serves as a member of the COG Solid Malignancies Integrated Translational Science Center Steering Committee, and on the Scientific Advisory Boards of the William Guy Forbeck Foundation, the Pablove Foundation, Curing Kids Cancer and the Sam Day Foundation.

Education and Training

  • Harvard University, Cambridge, MA — A.B. — 05/1986 — Biochemical Sciences
  • Washington University, St. Louis, MO — M.D. — 05/1993 — Medicine
  • Washington University, St. Louis, MO — Ph.D. — 05/1993 — Cell Biology
  • Brigham and Women's Hospital, Boston, MA — 06/1996 — Internal Medicine
  • Dana-Farber/Partners Cancer Care, Boston, MA — 06/1999 — Medical Oncology

Research Keywords

  • Childhood cancer
  • Sarcoma
  • Ewing sarcoma
  • Zebrafish models
  • Germ Cell Tumor
  • Wilms tumor
  • microRNA
  • Rhabdomyosarcoma

Publications

  • Tumor-associated stroma shapes the spatial tumor immune microenvironment of primary Ewing sarcomas. bioRxiv. 2025 Feb 06.. View in PubMed
  • Caveolin-1 regulates context-dependent signaling and survival in Ewing sarcoma. bioRxiv. 2025 Jan 28.. View in PubMed
  • Driver mutations associated with signatures of platinum sensitivity in germ cell tumors. NPJ Precis Oncol. 2024 Nov 02; 8(1):249.. View in PubMed
  • Origin of Ewing sarcoma by embryonic reprogramming of neural crest to mesoderm. bioRxiv. 2024 Oct 29.. View in PubMed
  • DROSHA Regulates Mesenchymal Gene Expression in Wilms Tumor. Mol Cancer Res. 2024 08 02; 22(8):711-720.. View in PubMed
  • Seed Becoming Soil: A New Paradigm of the Ewing Sarcoma Tumor Microenvironment. Clin Cancer Res. 2023 12 15; 29(24):5002-5004.. View in PubMed
  • Building advocacy into research. Dis Model Mech. 2023 Dec 01; 16(12).. View in PubMed
  • Refining the serum miR-371a-3p test for viable germ cell tumor detection. Sci Rep. 2023 06 29; 13(1):10558.. View in PubMed
  • Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence. Nat Commun. 2023 05 06; 14(1):2636.. View in PubMed
  • Specifications of the ACMG/AMP Variant Classification Guidelines for Germline DICER1 Variant Curation. Hum Mutat. 2023; 2023.. View in PubMed